CNBC's Jim Cramer said he's optimistic about CVS and explained to investors why he the healthcare company's stock is worth buying ...

A judge has now ruled a CVS partner will have to pay just under $289 million in a judgement. Nearly a decade ago a ...

This episode of Pharma Pulse covers a $290 million False Claims Act ruling against CVS Caremark, a new report showing most small medical practices fall short on HIPAA compliance, and research ...

With many PBMs receiving scrutiny, smaller startups that bill themselves as more transparent are seeing interest from employers in the state and nationally.

In this final video of a three-part video series, Joshua Fredell, Pharm.D., senior vice president at CVS Caremark and a ...

The lawsuit alleges civil violations of the Racketeer Influenced and Corrupt Organizations Act, or RICO, the Connecticut ...

A federal judge tripled damages against the pharmacy benefits manager after finding it encouraged inflated Medicare drug ...

The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...

A federal judge has ordered CVS Health's PBM Caremark to pay nearly $290 million after a whistleblower accused the business of overcharging Medicare on prescription drugs more than a decade ago.

CVS Health (CVS) won't include Gilead's (GILD) new HIV drug Yeztugo in its commercial healthcare plans, due to clinical, regulatory and financial factors. Read more here.

On Tuesday, Federal Court Judge Mitchell Goldberg issued a ruling that is the second staggering decision against Woonsocket-based CVS in recent weeks. Whistleblowers brought the two cases alleging ...